利妥昔单抗治疗ANCA相关性血管炎患者的严重感染分析
该研究回顾性分析了墨西哥城和瑞典隆德46例接受利妥昔单抗治疗的ANCA相关性血管炎患者,中位随访26个月。24%患者发生严重感染,感染率为11.5/100患者年,72%的感染发生在治疗第一年。多因素分析显示利妥昔单抗输注时年龄是严重感染的唯一独立预测因素。
要点
- 利妥昔单抗治疗ANCA相关性血管炎后严重感染常见,感染率11.5/100患者年。
- 多数严重感染(72%)发生于治疗第一年内,需加强早期监测。
- 利妥昔单抗输注时年龄较大是严重感染的独立预测因素。
核心结论
- 利妥昔单抗治疗后严重感染常见,感染相关死亡是主要担忧。
- 多数严重感染发生在利妥昔单抗治疗第一年内。
- 利妥昔单抗治疗时年龄较大独立预测严重感染。
研究设计与样本
- 中位随访时间从首次利妥昔单抗剂量至死亡或研究结束为26个月。
主要发现
- 11例(24%)患者共发生18次严重感染,感染率为11.5/100患者年。
- 严重感染的危险因素为利妥昔单抗起始时年龄较大和诊断时无耳鼻喉(ENT)受累。
- 多变量分析中,利妥昔单抗输注时年龄是预测严重感染的唯一独立因素。
- 随访期间4例(9%)患者死亡,均归因于感染。
临床怎么用
- 对接受利妥昔单抗治疗的ANCA相关性血管炎患者,尤其是年龄较大者,应警惕严重感染风险。
- 治疗第一年需加强感染监测和预防措施。
局限性
- 回顾性研究设计,样本量较小(46例),来自两个中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rituximab (RTX) is an anti-CD20 antibody that selectively depletes B cells and has emerged as a therapy for ANCA-associated vasculitis (AAV) during the past decade. This study sought to quantify and determine potential risk factors for severe infections in AAV patients treated with RTX at rheumatology clinics in Mexico City, Mexico and Lund, Sweden. METHODS: The study consisted of a retrospective case-record review (2005-15) with standardized data collection related to the occurrence of severe infection in 46 patients with AAV in Mexico City (n = 20) and Lund (n = 26) treated with RTX during their disease course. Median duration of follow-up from first RTX dose to death or end of study was 26 months. RESULTS: Eleven (24%) patients suffered a total of 18 severe infections (infection rate of 11.5/100 patient-years). Thirteen of the 18 infections (72%) occurred within the first year of treatment. Risk factors for severe infection were older age at RTX initiation and absence of ENT involvement at diagnosis. In multivariate analyses, age at RTX infusion was the only independent factor predicting severe infection. Four patients (9%) died during follow-up, all as a result of infection. CONCLUSION: Severe infections are common following RTX treatment, and mortality due to infection is a major concern. Most severe infections occur within the first year of RTX treatment. The negative correlation of ENT involvement with severe infection might reflect granulomatosis with polyangiitis phenotype heterogeneity. Older age at time of RTX treatment independently predicts severe infections.
引用
- Segelmark L, Flores-Suárez L, Mohammad A, et al. Severe infections in patients with ANCA-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2021. PMID: 33757116. doi:10.1093/rheumatology/keab293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。